Emergence of sentinel node biopsy in breast cancer as a standard-of-care in academic comprehensive cancer centers

Journal of the National Cancer Institute

Volumn 95, Issue 20, 2003, Pages 1514-1521

  Edge, Stephen B ^a   Niland, Joyce C ^b   Bookman, Michael A ^c   Theriault, Richard L ^d   Ottesen, Rebecca ^b   Lepisto, Eva ^e   Weeks, Jane C ^f  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e National Comprehensive Cancer Network   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CENTER; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONSERVATIVE TREATMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFORMATION PROCESSING; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SAFETY; SENTINEL LYMPH NODE BIOPSY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; AXILLA; BREAST TUMOR; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METHODOLOGY; MULTICENTER STUDY; PATHOLOGY; RISK; SEGMENTAL MASTECTOMY; STATISTICAL MODEL; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AXILLA; BREAST NEOPLASMS; CANCER CARE FACILITIES; FEMALE; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; NEOPLASM STAGING; ODDS RATIO; SENTINEL LYMPH NODE BIOPSY; UNITED STATES;

EID: 0142086449     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg076     Document Type: Article

References (48)

1. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 2002;20:3628-36.
2. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer 1995;76:1491-512.
3. Dees EC, Shulman LN, Souba WW, Smith BL. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection. Ann Surg 1997;226:279-86.
4. Liljegren G, Holmberg L. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast Cancer Study Group. Eur J Cancer 1997;33:193-9.
5. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992;66: 136-8.
6. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. J Natl Cancer Inst 2001;93:96-111.
7. Petrek JA, Meelan MC. Incidence of breast cancer-related lymphedema. Cancer 1998;83:2776-81.
8. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220: 391-8.
9. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-6.
10. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996;276:1818-22.
11. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000;18:2553-9.
12. Sener SF, Winchester DJ, Martz CH, Feldman JL, Cavanaugh JA, Winchester DP, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001;92:748-52.
13. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002;183:23-7.
14. Barnwell JM, Arredondo MA, Kollmorgen D, Gibbs JF, Lamonica D, Carson W, et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol 1998;5:126-30.
15. Moffat FL Jr, Ashikaga T, Krag DN. Sentinel node biopsy for breast cancer: showtime or dress rehearsal? In Vivo 2000;14:255-64.
16. Harlow SP, Krag DN. Sentinel lymph node - why study it: implications of the B-32 study. Semin Surg Oncol 2001;20:224-9.
17. Krag D. Why perform randomized clinical trials for sentinel node surgery for breast cancer? Am J Surg 2001;182:411-3.
18. Krag D, Ashikaga T, Abrams J. Sentinel nodes: clinical trial data needed. J Clin Oncol 2000;18:3873-4.
19. Edge SB, Hurd TC. Sentinel node update: breast cancer. Oncology (Huntingt) 1999;13:213-8.
20. Ross MI. Sentinel node dissection in early-stage breast cancer: ongoing prospective randomized trials in the USA. Ann Surg Oncol 2001;8(9 Suppl):77S-81S.
21. Kelemen PR. Comprehensive review of sentinel lymphadenectomy in breast cancer. Clin Breast Cancer 2000;1:111-25.
22. Giuliano AE. Current status of sentinel lymphadenectomy in breast cancer. Ann Surg Oncol 2001;8(9 Suppl):52S-55S.
23. Cox CE, Bass SS, McCann CR, Ku NN, Berman C, Durand K, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. Annu Rev Med 2000;51:525-42.
24. Update: NCCN practise guidelines for the treatment of breast cancer. National Comprehensive Cancer Network. Oncology (Huntingt) 1999;13: 41-66.
25. Tafra L, McMasters KM, Whitworth P, Edwards MJ. Credentialing issues with sentinel lymph node staging for breast cancer. Am J Surg 2000;180: 268-73.
26. Schwartz GF, Giuliano AE, Veronesi U, the Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biospy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002;94:2542-51.
27. Weeks JC. Outcomes assessment in the NCCN. Oncology (Huntingt) 1997; 11:137-40.
28. Niland J. NCCN outcomes research database: the first two years of data collection and analysis. Oncology (Huntingt) 1999;13(11A):575-8.
29. Niland JC. NCCN outcomes research database: data collection via the Internet. Oncology (Huntingt) 2000;14:100-3.
30. Fleming ID, Cooper JS, Henson ED, Hutter RV, Kennedy BJ, Murphy GP, et al., editors. Breast in AJCC cancer staging manual. 5th ed. Philadelphia (PA): Lippincott-Raven; 1997. p. 171-80.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
32. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care 1996;34:73-84.
33. Shivers S, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross M, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002;9:248-55.
34. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York (NY): John Wiley & Sons; 2000. p. 147-56.
35. Agresti A. Categorical data analysis. XV. New York (NY): John Wiley & Sons; 1990. p. 234-5.
36. Lucci A Jr, Kelemen PR, Miller C 3rd, Chardkoff L, Wilson L. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 2001;192:453-8.
37. Davis KG, Schriver JP, Waddell B. Implementation of sentinel lymph node biopsy for breast cancer by surgeons in the Department of Defense. Am J Surg 2002;184:94-6.
38. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998;227:645-51.
39. Cody HS 3rd. Sentinel lymph node mapping in breast cancer. Oncology (Huntingt) 1999;13:25-34.
40. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345-50.
41. Veronesi U, Paganelli G, Viale G, Galimberti V, Luini A, Zurrida S, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999;91:368-73.
42. Veronesi U, Galimberti V, Zurrida S, Pigatto F, Veronesi P, Robertson C, et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 2001;37:454-8.
43. Bass SS, Cox CE, Reintgen DS. Learning curves and certification for breast cancer lymphatic mapping. Surg Oncol Clin N Am 1999;8:497-509.
44. Cox CE, Salud CJ, Cantor A, Bass SS, Peltz ES, Ebert MD, et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593-600.
45. Euhus DM, Peters GN, Leitch AM, Saboorian H, Mathews D, Erdman W, et al. Validating the performance of the mammary sentinel lymph node team. J Surg Oncol 2002;79:209-15.
46. Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001;233: 51-9.
47. McMasters KM, Wong SL, Chao C, Woo C, Tuttle TM, Noyes RD, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 2001;234:292-9.
48. Cody HS 3rd, Hill AD, Tran KN, Brennan MF, Borgen PI. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg 1999;229:723-6.